Pricing Log in Create free account
Friday 6 November 2026 Export VRDN’s income statement to Excel — free account

Viridian Therapeutics, Inc.

VRDN Healthcare Biotechnology

Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.

Revenue
−63.5%
EPS
−5.00%
Free cash flow
−9.92%
Total debt
+1,064.9%

Quarter to September 2026, against a year earlier

28.74 0.19 +0.67%
Market cap
$3.2B
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
3/9
Altman Z
6.69
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Viridian Therapeutics, Inc. (VRDN) Debt to equity

Alert me on Debt to equity

Viridian Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.1× from fiscal 2025 (0.1×). Over the past ten years it has ranged from 0.0× (fiscal 2015) to 0.3× (fiscal 2019); the current reading is higher than 64% of that period. That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.1× 126.14%
FY2024 0.0× (33.04%)
FY2023 0.0× 287.29%
FY2022 0.0× 321.43%
FY2021 0.0× 600.00%
FY2020 0.0× (99.85%)
FY2019 0.3× 76.20%
FY2018 0.2× (39.48%)
FY2017 0.3× 37.53%
FY2016 0.2× —

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× —
Jun 2026 0.4× 361.16%
Mar 2026 0.1× 14.60%
Dec 2025 0.1× 66.75%
43 more quarters

Against its own ten years

Low 0.0× High 0.3×
Ten-year median 0.0×
Current reading's percentile 64

Debt to equity against peers

Company Debt to equity
CELC Celcuity, Inc. compare −58.9×
VRDN Viridian Therapeutics, Inc. 0.0×
IDYA IDEAYA Biosciences, Inc. compare 0.0×
ELVN Enliven Therapeutics, Inc. compare 0.0×
DNLI Denali Therapeutics Inc. compare 0.0×
DYN Dyne Therapeutics, Inc. compare 0.3×
VKTX Viking Therapeutics, Inc. compare 0.4×
TARS Tarsus Pharmaceuticals, Inc. compare 0.7×
TLX Telix Pharmaceuticals Limited compare 1.2×
Biotechnology industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on VRDN